Amyotrophic Lateral Sclerosis Therapeutics Market
PUBLISHED: 2024 ID: SMRC27403
SHARE
SHARE

Amyotrophic Lateral Sclerosis Therapeutics Market

Amyotrophic Lateral Sclerosis Therapeutics Market Forecasts to 2030 - Global Analysis By Drug Type (Riluzole, Edaravone, Investigational Drugs and Other Drug Types), Action Mechanism, Route Of Administration, Disease Stage, Application, End User and By Geography

4.9 (33 reviews)
4.9 (33 reviews)
Published: 2024 ID: SMRC27403

This report covers the impact of COVID-19 on this global market
Loading...

Years Covered

2022-2030

Estimated Year Value (2024)

US $0.86 BN

Projected Year Value (2030)

US $2.31 BN

CAGR (2024 - 2030)

12.6%

Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

Asia Pacific

Highest Growing Market

North America


According to Stratistics MRC, the Global Amyotrophic Lateral Sclerosis Therapeutics Market is accounted for $0.86 billion in 2024 and is expected to reach $2.31 billion by 2030 growing at a CAGR of 12.6% during the forecast period. Amyotrophic Lateral Sclerosis (ALS) therapeutics encompass a range of treatments aimed at managing symptoms, slowing disease progression, and improving quality of life for individuals with ALS, a neurodegenerative disorder affecting motor neurons in the brain and spinal cord. Therapeutics help alleviate symptoms such as muscle weakness, spasticity, and pain, improving patient comfort and quality of life.

According to the data published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, in 2015 around 16,583 cases of amyotrophic lateral sclerosis were identified in the USA.

Market Dynamics: 

Driver: 

Increasing incidence rates

As more individuals are diagnosed with ALS, the demand for effective treatment options rises, driving research and development investments. Pharmaceutical companies are incentivized to innovate, leading to the introduction of novel therapies and clinical trials. Furthermore, heightened awareness and advocacy for ALS lead to increased funding and support for research initiatives. This growing patient population, coupled with advancements in understanding the disease, fuels market expansion by promoting the development of targeted and personalized treatment solutions.

Restraint:

Complex regulatory pathways

Complex regulatory pathways in Amyotrophic Lateral Sclerosis (ALS) therapeutics stem from the disease's rarity and its multifaceted nature. The need for extensive clinical trials, often involving diverse patient populations, can delay drug approvals. Stringent requirements for demonstrating efficacy and safety further complicate the process. Consequently, the slow progression of novel therapies reaching the market limits treatment options for patients and hampers overall market growth.

Opportunity:

Growing emphasis on multidisciplinary care and supportive therapies

ALS therapeutics approach integrates neurology, respiratory therapy, nutrition, and palliative care, enhancing patient quality of life and treatment outcomes. Collaborative care models promote the development of comprehensive treatment plans, driving demand for innovative therapeutics and supportive interventions. Additionally, heightened awareness of ALS and the need for personalized care encourage research investments and partnerships, leading to the emergence of novel therapies. This holistic approach fosters greater patient adherence and satisfaction, further propelling market growth.

Threat:

High treatment costs

High treatment costs in ALS therapeutics stem from the complexity of the disease, the need for advanced medications, and ongoing supportive therapies. Innovative treatments, often in limited supply, require significant research and development investment, resulting in elevated prices. These high costs can limit patient access, create financial burdens, and reduce adherence to treatment regimens. Consequently, this hampers market growth by restricting the patient population and reducing overall demand for ALS therapeutics, thus impacting the potential for new product development and market expansion.

Covid-19 Impact

The covid-19 pandemic significantly impacted the ALS therapeutics market by disrupting clinical trials and research activities, delaying the development and approval of new therapies. Patients faced challenges in accessing healthcare services, leading to interrupted treatment regimens and decreased patient monitoring. Additionally, the focus on COVID-19 diverted resources and funding away from ALS research. However, the pandemic also increased telehealth adoption, allowing for continued patient support and consultations, potentially benefiting long-term care strategies for ALS patients.

The riluzole segment is expected to be the largest during the forecast period

The riluzole segment is predicted to secure the largest market share throughout the forecast period. Riluzole is an FDA-approved drug used in the treatment of Amyotrophic Lateral Sclerosis (ALS). It is classified as a glutamate antagonist, working primarily by inhibiting the release of glutamate, a neurotransmitter that can contribute to neuronal damage when present in excess. Riluzole is shown to slow disease progression and extend survival in ALS patients, making it a critical therapeutic option. 

The experimental therapies segment is expected to have the highest CAGR during the forecast period

The experimental therapies segment is anticipated to witness the highest CAGR during the forecast period. Experimental therapies for ALS offer promising benefits by targeting the disease's underlying mechanisms. By focusing on personalized medicine, these experimental treatments aim to enhance patient outcomes and quality of life. Moreover, they contribute to a deeper understanding of ALS, paving the way for future breakthroughs and expanding the therapeutic landscape for affected individuals.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period due to increasing awareness of the disease and rising incidence rates. Countries like Japan, China, and India are focusing on enhancing research and development efforts for effective therapies. Government initiatives aimed at improving healthcare infrastructure and patient access to treatments further support market expansion. Additionally, the growing emphasis on supportive care options enhances the overall management of ALS in this region.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period driven by advanced healthcare infrastructure and significant investment in research and development. The United States and Canada are leading in clinical trials for innovative therapies, with a focus on gene therapy and novel drug formulations. The presence of major pharmaceutical companies enhances competition and accelerates the development of effective ALS therapies. Additionally, comprehensive supportive care services improve patient outcomes and quality of life. 

Key players in the market

Some of the key players profiled in the Amyotrophic Lateral Sclerosis Therapeutics Market include Teva Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., Eli Lilly and Company, Amgen Inc., Sanofi, Biogen Inc., Ionis Pharmaceuticals Inc., Orphazyme A/S, Regeneron Pharmaceuticals Inc., Reata Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Wave Life Sciences Limited, Cytokinetics Incorporated, NeuroSense Therapeutics Limited and Coya Therapeutics.

Key Developments:

In August 2024, NeuroSense Therapeutics Ltd. announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM), which evaluated the safety and efficacy of PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS). This data provides additional insights that align with the Company's recent announcements of improved survival by 43% and slowed disease progression by 36%.

In June 2024, Coya Therapeutics recently announced the publication of a Phase 1 clinical trial that evaluated a novel combination therapy for Amyotrophic Lateral Sclerosis (ALS) in the peer-reviewed journal Frontiers in Neurology. The study explored the effects of a combination of CTLA4-Ig and low-dose interleukin-2 (IL-2) on ALS patients.

Drug Types Covered:
• Riluzole
• Edaravone
• Investigational Drugs
• Other Drug Types

Action Mechanisms Covered:
• Glutamate Inhibitors
• Free Radical Scavengers
• Neuroprotective Agents
• Combination Therapies
• Other Action Mechanisms

Route Of Administrations Covered:
• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Disease Stages Covered:
• Early Stage
• Moderate Stage
• Advanced Stage

Applications Covered:
• Symptomatic Treatments
• Nutritional Support
• Respiratory Therapies
• Physical & Occupational Therapy
• Experimental Therapies
• Complementary Therapies
• Other Applications

End Users Covered:
• Hospitals
• Specialty Clinics
• Homecare Settings
• Research Institutions
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary   
     
2 Preface    

 2.1 Abstract   
 2.2 Stake Holders  
 2.3 Research Scope  
 2.4 Research Methodology 
  2.4.1 Data Mining 
  2.4.2 Data Analysis 
  2.4.3 Data Validation 
  2.4.4 Research Approach 
 2.5 Research Sources  
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions 
     
3 Market Trend Analysis  
 3.1 Introduction  
 3.2 Drivers   
 3.3 Restraints  
 3.4 Opportunities  
 3.5 Threats   
 3.6 Application Analysis 
 3.7 End User Analysis  
 3.8 Emerging Markets  
 3.9 Impact of Covid-19  
     
4 Porters Five Force Analysis  
 4.1 Bargaining power of suppliers 
 4.2 Bargaining power of buyers 
 4.3 Threat of substitutes 
 4.4 Threat of new entrants 
 4.5 Competitive rivalry  
     
5 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Drug Type
 5.1 Introduction  
 5.2 Riluzole   
 5.3 Edaravone  
 5.4 Investigational Drugs 
 5.5 Other Drug Types  
     
6 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Action Mechanism
 6.1 Introduction  
 6.2 Glutamate Inhibitors 
 6.3 Free Radical Scavengers 
 6.4 Neuroprotective Agents 
 6.5 Combination Therapies 
 6.6 Other Action Mechanisms 
     
7 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Route Of Administration
 7.1 Introduction  
 7.2 Oral   
 7.3 Intravenous  
 7.4 Subcutaneous  
 7.5 Intramuscular  
     
8 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Disease Stage
 8.1 Introduction  
 8.2 Early Stage  
 8.3 Moderate Stage  
 8.4 Advanced Stage  
     
9 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Application
 9.1 Introduction  
 9.2 Symptomatic Treatments 
 9.3 Nutritional Support  
 9.4 Respiratory Therapies 
 9.5 Physical & Occupational Therapy
 9.6 Experimental Therapies 
 9.7 Complementary Therapies 
 9.8 Other Applications  
     
10 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By End User
 10.1 Introduction  
 10.2 Hospitals   
 10.3 Specialty Clinics  
 10.4 Homecare Settings  
 10.5 Research Institutions 
 10.6 Other End Users  
     
11 Global Amyotrophic Lateral Sclerosis Therapeutics Market, By Geography
 11.1 Introduction  
 11.2 North America  
  11.2.1 US  
  11.2.2 Canada  
  11.2.3 Mexico  
 11.3 Europe   
  11.3.1 Germany  
  11.3.2 UK  
  11.3.3 Italy  
  11.3.4 France  
  11.3.5 Spain  
  11.3.6 Rest of Europe 
 11.4 Asia Pacific  
  11.4.1 Japan  
  11.4.2 China  
  11.4.3 India  
  11.4.4 Australia  
  11.4.5 New Zealand 
  11.4.6 South Korea 
  11.4.7 Rest of Asia Pacific 
 11.5 South America  
  11.5.1 Argentina 
  11.5.2 Brazil  
  11.5.3 Chile  
  11.5.4 Rest of South America
 11.6 Middle East & Africa 
  11.6.1 Saudi Arabia 
  11.6.2 UAE  
  11.6.3 Qatar  
  11.6.4 South Africa 
  11.6.5 Rest of Middle East & Africa
     
12 Key Developments   
 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
 12.2 Acquisitions & Mergers 
 12.3 New Product Launch 
 12.4 Expansions  
 12.5 Other Key Strategies 
     
13 Company Profiling   
 13.1 Teva Pharmaceutical Industries Limited
 13.2 Novartis AG  
 13.3 Pfizer Inc.  
 13.4 Eli Lilly and Company 
 13.5 Amgen Inc.  
 13.6 Sanofi   
 13.7 Biogen Inc.  
 13.8 Ionis Pharmaceuticals Inc. 
 13.9 Orphazyme A/S  
 13.10 Regeneron Pharmaceuticals Inc.
 13.11 Reata Pharmaceuticals Inc. 
 13.12 Apellis Pharmaceuticals Inc. 
 13.13 Wave Life Sciences Limited 
 13.14 Cytokinetics Incorporated 
 13.15 NeuroSense Therapeutics Limited
 13.16 Coya Therapeutics  
     
List of Tables    
1 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Region (2022-2030) ($MN)
2 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Drug Type (2022-2030) ($MN)
3 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Riluzole (2022-2030) ($MN)
4 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Edaravone (2022-2030) ($MN)
5 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Investigational Drugs (2022-2030) ($MN)
6 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other Drug Types (2022-2030) ($MN)
7 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Action Mechanism (2022-2030) ($MN)
8 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Glutamate Inhibitors (2022-2030) ($MN)
9 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Free Radical Scavengers (2022-2030) ($MN)
10 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Neuroprotective Agents (2022-2030) ($MN)
11 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Combination Therapies (2022-2030) ($MN)
12 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other Action Mechanisms (2022-2030) ($MN)
13 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Route Of Administration (2022-2030) ($MN)
14 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Oral (2022-2030) ($MN)
15 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Intravenous (2022-2030) ($MN)
16 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Subcutaneous (2022-2030) ($MN)
17 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Intramuscular (2022-2030) ($MN)
18 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Disease Stage (2022-2030) ($MN)
19 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Early Stage (2022-2030) ($MN)
20 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Moderate Stage (2022-2030) ($MN)
21 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Advanced Stage (2022-2030) ($MN)
22 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Application (2022-2030) ($MN)
23 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Symptomatic Treatments (2022-2030) ($MN)
24 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Nutritional Support (2022-2030) ($MN)
25 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Respiratory Therapies (2022-2030) ($MN)
26 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Physical & Occupational Therapy (2022-2030) ($MN)
27 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Experimental Therapies (2022-2030) ($MN)
28 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Complementary Therapies (2022-2030) ($MN)
29 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other Applications (2022-2030) ($MN)
30 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By End User (2022-2030) ($MN)
31 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Hospitals (2022-2030) ($MN)
32 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Specialty Clinics (2022-2030) ($MN)
33 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Homecare Settings (2022-2030) ($MN)
34 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Research Institutions (2022-2030) ($MN)
35 Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook, By Other End Users (2022-2030) ($MN)
     
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

List of Figures

RESEARCH METHODOLOGY


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.


Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.


For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials